גרנוסייט 34 Izrael - hebrejština - Ministry of Health

גרנוסייט 34

sanofi - aventis israel ltd - lenograstim 33.6 miu/ml - lyophilized powder for injection - lenograstim - - reduction in duration of neutropenia and associated complications in patients undergoing bone marrow transplantation or cytotoxic chemotherapy associated with a febrile neutropenia. - autologous mobilization of peripheral blood progenitor cells. as an adjunct to allogenic mobilization of peripheral blood progenitor cells (pbpcs).

ערבה 100 מ"ג Izrael - hebrejština - Ministry of Health

ערבה 100 מ"ג

sanofi - aventis israel ltd - leflunomide 100 mg - film coated tablets - leflunomide - arava is indicated in adults for the treatment of active rheumatoid arthritis (ra) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing 3. to imptove physical function. arava is indicated for the treatment of adult patients with active psoriatic arthritis.

אופטיקרום טפות עיניים Izrael - hebrejština - Ministry of Health

אופטיקרום טפות עיניים

sanofi - aventis israel ltd - cromoglicic acid as sodium 2 %w/v - eye drops - cromoglicic acid - preventive treatment for all types of allergic conjunctivitis.

טאילביסט Izrael - hebrejština - Ministry of Health

טאילביסט

sanofi - aventis israel ltd - nedocromil sodium 2 %w/v - eye drops - nedocromil - tilavist is indicated for the prophylaxis, relief and treatment of allergic conjunctivitis, including seasonal allergic conjunctivitis, perennial allergic conjunctivitis and vernal keratoconjunctivitis.

דפלפט כרונו 500 מג Izrael - hebrejština - Ministry of Health

דפלפט כרונו 500 מג

sanofi - aventis israel ltd - valproic acid; valproic acid as sodium - טבליות בשחרור ממושך - valproic acid 145 mg; valproic acid as sodium 333 mg - valproic acid

רוליד 150 מג Izrael - hebrejština - Ministry of Health

רוליד 150 מג

sanofi - aventis israel ltd - roxithromycin - טבליות מצופות פילם - roxithromycin 150 mg - roxithromycin

מאלוקס פלוס תרחיף Izrael - hebrejština - Ministry of Health

מאלוקס פלוס תרחיף

sanofi - aventis israel ltd - aluminium hydroxide; magnesium hydroxide; simethicone - תרחיף - aluminium hydroxide 175 mg / 5 ml; magnesium hydroxide 200 mg / 5 ml; simethicone 25 mg / 5 ml - antacids with antiflatulents - antacid, antiflatulent, relief of sensation of heatburn.

רנג'ל טבליות 800 מ"ג Izrael - hebrejština - Ministry of Health

רנג'ל טבליות 800 מ"ג

sanofi - aventis israel ltd - sevelamer hydrochloride 800 mg - film coated tablets - sevelamer - reduction of serum phosphorus in patients with end stage renal disease ( esrd) . the safety and efficacy of renagel in esrd patients who are not on hemodialysis have not been studied. in hemodialysis patients renagel decreases the incidence of hypercalcemic episodes relative to patients on calcium acetate treatment.

רנוולה  טבליות 800 מג Izrael - hebrejština - Ministry of Health

רנוולה טבליות 800 מג

sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

רנוולה אבקה 2.4 גרם Izrael - hebrejština - Ministry of Health

רנוולה אבקה 2.4 גרם

sanofi israel ltd - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g/sachet - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney diseasenot on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.